Granulomatous Interstitial Nephritis: Diagnostic Workup for Underlying Etiology

Authored by Sourabh Sharma, published on 2026-11-16 13:14:08.0

  1. Confirm Biopsy-Proven GIN in Unexplained AKI or Progressive CKD With Sterile Pyuria, Hematuria, or Low-Grade Proteinuria
    • Characterize Granulomas, Infiltrate, IFTA, Vasculitis, and Foreign Material; Request AFB, PAS, GMS, Culture, and PCR
      • Review Medication Timeline, TB Risk, Immunosuppression, Travel, Occupation, and Systemic Features
        • Obtain CBC, ESR/CRP, Renal Panel, Urine Studies, HIV, Calcium, Chest Imaging, ANCA, and Risk-Directed Infection Tests
          • Withhold Empirical Immunosuppression Until Important TB and Fungal Infection Are Adequately Evaluated
            • Which Etiology Is Supported by Integrated Histology, Clinical, Imaging, and Microbiological Findings?
              • Obtain Urine and Site-Directed Mycobacterial or Fungal Culture, NAAT, Antigen Testing, and Extrapulmonary Tissue
                • TB, NTM, or Fungal Infection Confirmed?
                  • Classify as Confirmed Infectious GIN and Follow Organism-Specific Pathway
                  • Does Important TB, NTM, or Fungal Infection Remain Plausible Despite Negative Tests?
                    • Defer Immunosuppression; Obtain Infectious Diseases Review and Additional Microbiological or Tissue Testing
                    • Reassess Drugs and Occult Infection With Multidisciplinary Review and Additional Tissue Testing
                      • Underlying Cause Identified After Expanded Evaluation?
                        • Classify Identified Etiology and Follow Cause-Specific Management Pathway
                        • Classify as Idiopathic GIN Only After Adequate Exclusion and Continue Surveillance
                        • Defer Immunosuppression; Obtain Infectious Diseases Review and Additional Microbiological or Tissue Testing
              • Withdraw Suspected Culprit Drug and Exclude Infection and Systemic Disease
                • Classify as Drug-Induced GIN
              • Evaluate PR3/MPO-ANCA, ENT, Pulmonary, and Systemic Vasculitis; Exclude Infection Mimics
                • Systemic or Renal-Limited Vasculitis Confirmed?
                  • Classify as Vasculitis-Associated GIN and Follow Vasculitis Pathway
                  • Reassess Drugs and Occult Infection With Multidisciplinary Review and Additional Tissue Testing
                    • Underlying Cause Identified After Expanded Evaluation?
                      • Classify Identified Etiology and Follow Cause-Specific Management Pathway
                      • Classify as Idiopathic GIN Only After Adequate Exclusion and Continue Surveillance
                      • Defer Immunosuppression; Obtain Infectious Diseases Review and Additional Microbiological or Tissue Testing
              • Assess Sarcoidosis Organs and Biopsy Accessible Extrarenal Disease; Treat ACE as Supportive Only
                • Sarcoidosis Probable After Adequate Infection Exclusion?
                  • Classify as Probable Sarcoidosis-Associated GIN
                  • Reassess Drugs and Occult Infection With Multidisciplinary Review and Additional Tissue Testing
                    • Underlying Cause Identified After Expanded Evaluation?
                      • Classify Identified Etiology and Follow Cause-Specific Management Pathway
                      • Classify as Idiopathic GIN Only After Adequate Exclusion and Continue Surveillance
                      • Defer Immunosuppression; Obtain Infectious Diseases Review and Additional Microbiological or Tissue Testing
              • Perform Ocular Examination for Bilateral Anterior Uveitis; Evaluate Crohn's, Foreign Body, Systemic, Malignancy, and Allograft Causes
                • TINU or Another Granulomatous Disorder Established?
                  • Classify TINU or Other Identified Systemic Cause and Follow Cause-Specific Pathway
                  • Reassess Drugs and Occult Infection With Multidisciplinary Review and Additional Tissue Testing
                    • Underlying Cause Identified After Expanded Evaluation?
                      • Classify Identified Etiology and Follow Cause-Specific Management Pathway
                      • Classify as Idiopathic GIN Only After Adequate Exclusion and Continue Surveillance
                      • Defer Immunosuppression; Obtain Infectious Diseases Review and Additional Microbiological or Tissue Testing
              • Reassess Drugs and Occult Infection With Multidisciplinary Review and Additional Tissue Testing
                • Underlying Cause Identified After Expanded Evaluation?
                  • Classify Identified Etiology and Follow Cause-Specific Management Pathway
                  • Classify as Idiopathic GIN Only After Adequate Exclusion and Continue Surveillance
                  • Defer Immunosuppression; Obtain Infectious Diseases Review and Additional Microbiological or Tissue Testing
tosprivacy